Evalution of the granisetron instead of ondansetron in the emergency room

Evalution of the granisetron instead of ondansetron

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230726058930N3

Enrollment

100

Registered

2024-01-20

Start date

2024-02-01

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea and vomiting. Nausea and vomiting

Interventions

Intervention 1: Intervention group: A vial of 3 mg intravenous granisetron. Intervention 2: Control group: 4 mg of intravenous ondansetron.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Nausea Vomit

Exclusion criteria

Exclusion criteria: Patients with symptoms such as headaches, lateralized symptoms, and unstable vital signs. Patients who have chest pain or ECG changes. Patients with symptoms of Rise ICP. Patients who have used drugs that increase serotonin (such as fluoxetine, doxepin, isomerbuxazid, amitriptyline, etc.) in the last few days. Patients who have used drugs that increase serotonin (such as fluoxetine, doxepin, isomerbuxazid, amitriptyline, etc.) in the last few days. Patients who have consumed grapefruit in the past 24 hours Patient does not consent to attend or continue treatment.

Design outcomes

Primary

Measure	Time frame
Nausea and vomiting. Timepoint: 30, 15, 45, 60, 75 and 95 minutes after intravenous granisetron injection. Method of measurement: Visual Analogue Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Vefagh nematollahi

Ahvaz University of Medical Sciences

vefagh.a@ajums.ac.ir+98 61 3392 5320

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026